"We think the mega deal size reflects [the] market's bet that well-established leading Chinese pharmaceutical firms in terms of revenue, profit, market share and so forth, like Hansoh, could have a better chance to stand out in the growing Chinese pharmaceutical sector."
Jialin Zhang, senior research analyst of China health care at ICBC International Research Ltd., commenting on Hansoh Pharmaceutical Group Co. Ltd. raising $1 billion on Hong Kong's stock market

"Metagenomic next-generation sequencing is the use of next-generation sequencing technology – the ability to generate millions of sequence reads from a clinical sample – for infectious disease diagnosis by identifying tell-tale DNA signatures from pathogens. It is called 'metagenomic' because you are sequencing all of the nucleic acid (DNA and RNA) present in the clinical sample, with the goal of identifying the exceedingly small proportion of sequence reads that may correspond to pathogens, looking for the proverbial 'needle-in-a-haystack.'"
Charles Chiu, professor of laboratory medicine and medicine at UCSF and senior author of a study published in The New England Journal of Medicine

"We've been interested in the protein degrader approach for a number of years and following the field as it matured. What ultimately attracted us to select Nurix was their deep expertise in the biology of E3 ligases, understanding that from a number of different angles, including the degradation angle."
Linda Higgins, senior vice president of biology at Gilead Sciences Inc., on the partnership deal with Nurix Therapeutics Inc. to discover, develop and commercialize several new drugs for cancer and other challenging diseases

"We're at a technology transition point from modifying what exists in nature, which has been the traditional approach to protein engineering, to using first principles to build proteins from scratch to have exactly the properties you want. We can now design proteins that have specific functions, and that is where our work starts tying into medicine, and why we are very excited to be working with Amgen."
David Baker, the founder and director of the University of Washington's Institute for Protein Design, which has established a collaboration with Amgen Inc.